LONDON, ENGLAND, March 09, 2013 /24-7PressRelease/
-- Hair loss is one of the most obvious and unwanted side effects of chemotherapy treatment for cancer patients but help is on the way for sufferers in the Bristol and Bath areas. The CircleBath Hospital, which serves the region, has now adopted the DigniCap System, recognised as the most scientifically advanced treatment available, as its preferred treatment for hair loss.
Developed by Dignitana AB, a Swedish company that is a world leader in the field of scalp-cooling technology, the DigniCap System is an effective, comfortable and safe hair-loss prevention treatment. It is the only one that provides scalp cooling at temperatures above freezing; its built-in temperature sensors and precision cooling mechanism facilitate gradual and tolerable temperature fluctuations on the scalp. The system offers continuous monitoring for comfort and consistent treatment application, as well as caps that do not cover the ears so that the patients can still hear during treatment. It also features an intuitive touch-screen control panel.
Clinical trials conducted at leading medical centres worldwide have shown that the DigniCap System
is effective for preventing hair loss during chemotherapy in both men and women of various ethnic groups; some 80% of women in Asia and Europe who used the system retained their hair. The results of further investigations into the system in the UK and USA are scheduled to be presented via conferences and publications during 2013.
Specialist nurses at CircleBath, considered by some to be among the finest private hospitals in Britain
, chose the DigniCap System after personally testing a number of alternatives. Their decision was based on the superior comfort and effectiveness of the system. The first scalp cooling system to be backed by clinical evidence that shows consistent results at above freezing temperatures, DigniCap results in less stress and greater comfort for the patient.
Commenting that CircleBath patients deserve the best treatment available, Lead Nurse for CircleBath Oncology said, ""We researched, deliberated and compared clinical and technical aspects of several scalp-cooling treatments before making our final decision. Then we decided that we needed to try the caps ourselves before offering them to our patients. DigniCap was eminently more comfortable and user-friendly. Add to that the assurance of clinically proven safety, and there was really no debate - DigniCap was our unequivocal choice."
For his part, Dignitana CEO Martin Waleij has said, "At CircleBath, patients know they are always getting the best treatment possible. We are proud they have chosen to offer their patients the DigniCap System - a 21st Century solution for a 21st Century healthcare establishment. It is an honour to be able to add CircleBath Hospital to the growing list of top medical establishments around the world that include the DigniCap System in their comprehensive approach to cancer care."
Anyone wanting to know more about the DigniCap System offered at CircleBath Hospital is invited to email the Hospital at firstname.lastname@example.org
for further information.About Circle
The Company's principal asset is its holding in Circle Health Limited ("Circle Health"), an employee co-owned healthcare provider. Circle Health is 50.1 per cent. owned by the Company and 49.9 per cent. owned by the Circle Partnership Limited which is 100 per cent. beneficially owned by the group's clinicians and employees.
Circle's objective is to redefine secondary healthcare delivery in the UK. It benefits from a unique operating model which has been successfully applied and proven, whereby clinicians are empowered to achieve high levels of patient care and efficiency, though co-ownership and active participation in managing operations.
The Company is a Jersey incorporated company and the rights of shareholders may be different from the rights of shareholders in a UK incorporated company.
Press release service and press release distribution provided by http://www.24-7pressrelease.com
# # #Read more Press Releases from Christina Robinson: